logo
Plus   Neg
Share
Email

European Medicines Agency Approves Safety Label Update For Novartis' Beovu - Quick Facts

Novartis AG (NVS) announced Monday that the Committee for Medicinal Products for Human Use (CHMP), has approved an update to the Beovu (brolucizumab) Summary of Product Characteristics (SmPC) to include additional information regarding retinal vasculitis and retinal vascular occlusion.

Typically, these events occurred in the presence of intraocular inflammation. This approval follows Novartis' announcement that it would pursue worldwide label updates after a review and further characterization of post-marketing safety events reported to Novartis.

Novartis worked with the EMA to update the Beovu (brolucizumab) label to guide physicians in their treatment of wet AMD. The update includes the additional characterization of retinal vasculitis and/or retinal vascular occlusion, typically in the presence of intraocular inflammation

The label update is applicable to all 27 European Union member states as well as the UK, Iceland, Norway and Liechtenstein. Beovu is now approved for the treatment of wet AMD in more than 40 countries, including in the US, EU, UK, Japan, Canada and Australia.

Beovu (brolucizumab, also known as RTH258) is the most clinically advanced humanized single-chain antibody fragment (scFv). It is approved in more than 40 countries, including in the US, EU, UK, Japan, Canada and Australia, based on the results of the HAWK and HARRIER clinical trials.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Santa Cruz Bicycles LLC has recalled certain model year 2020 bicycles with aluminum frames citing fall risks, according to the U.S. Consumer Product Safety Commission. The recall involves about 2,900 units of model year 2020 Auminum Santa Cruz and Juliana Bicycles. In addition, about 216 were sold in Canada. AstraZeneca is mulling an additional global trial to confirm the 90% efficacy rate of its Covid-19 vaccine candidate at lower dosage, Bloomberg news quoted Chief Executive Officer Pascal Soriot as saying. In an interview, Soriot noted that instead of adding the trial to an ongoing U.S. process, the company might launch a fresh study to evaluate efficacy of lower dosage of its vaccine that perform U.S. airline Delta Air Lines, Inc. and its Italian codeshare partner Alitalia are planning to launch quarantine-free, COVID-free flights between U.S. and Europe through new testing protocols, starting in December. In a statement, Delta said it has signed deals with airports and governments eliminating quarantine requirements on COVID-tested flights connecting Atlanta and Rome.
Follow RTT